Compugen Ltd. (CGEN)
| Previous close | 2.1300 |
| Open | 2.1000 |
| Bid | 2.0400 x 100 |
| Ask | 2.1300 x 100 |
| Day's range | 2.0650 - 2.1200 |
| 52-week range | 0.5300 - 3.0300 |
| Volume | |
| Avg. volume | 482,752 |
| Market cap | 191.784M |
| Beta (5Y monthly) | 2.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
PR NewswireCompugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
Simply Wall St.We're Not Worried About Compugen's (NASDAQ:CGEN) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Compugen...
PR NewswireCompugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) annual meeting on May31-June 4 2023, in Chicago, Illinois.
